The U.S. Centers for Medicare and Medicaid Services (CMS) has scheduled a meeting for January 30, 2013, to review evidence on the use of beta-amyloid PET imaging for managing dementia and neurodegenerative disease.
Specifically, CMS is interested in public testimony on the clinical impact on health outcomes experienced by patients who are afflicted with neurodegenerative diseases, such as Alzheimer's. Medicare currently does not reimburse for beta-amyloid PET imaging.
Certain PET tracers can image beta-amyloid plaque in the brain, which has been linked to cognitive impairment and decline.
